Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer

50 patients with loco-recurrent squamous-cell cancer after curative esophagectomy were retrospectively analyzed. Patients were treated with radiotherapy (median 60？Gy) combined with chemotherapy consisting of either 5-fluorouracil (5-FU) plus cisplatin (DDP) (R-FP group) or paclitaxel plus DDP (R-TP group).The median follow-up period was 16.0？months. The 1-year and 3-year survival rates were 56% and 14%, respectively. The median progression-free survival (PFS) and overall survival (OS) time was 9.8 and 13.3？months respectively. There was no statistical significance of the PFS of the two groups. The OS (median 16.3？months) in the R-TP group was superior to that in the R-FP group (median: 9.8？months) (p？=？0.012). Among the patients who had received ≥60？Gy irradiation dose, the median PFS (10.6？months) and OS (16.3？months) were significantly superior to the PFS (8.7？months) and OS (11.3？months) among those patients did not (all p？<？0.05). Grade 3 treatment-related gastritis were observed in 6 (27.3%) and 7 (25%) patients in the R-FP and R-TP group respectively. By univariate survival analysis, the age (<60？years), TP regimen and higher irradiation dose might improve the OS of such patients in present study.For those patients with post-operative loco-recurrent squamous-cell esophageal carcinoma, radiotherapy combined with either FP or TP regimen chemotherapy was an effective salvage treatment. Younger age, treatment with the TP regimen and an irradiation dose ≥60？Gy might improve the patients’ treatment outcome.